Tagraxofusp-erzs OverviewTagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018, and after a second review, in the EU in January 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Tagraxofusp is a fusion protein consisting of i...
Read more Tagraxofusp-erzs Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tagraxofusp-erzs
Recent Tagraxofusp-erzs Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Solution: 1000mcg
Other drugs which contain Tagraxofusp-erzs or a similar ingredient: (1 result)
- ELZONRIS Tagraxofusp-erzs